Scrip, Citeline Commercial

@PharmaScrip

Scrip goes beyond the headlines to deliver insight & analysis on drug discovery, development and product life cycle value chain.

Global

Joined February 2009

2KFollowing

22KFollowers

Pinned

Scrip, Citeline Commercial@PharmaScrip · Jul 25

Gilead’s Yeytuo, Lilly’s Kisunla Headline CHMP Positive Opinions — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3z86k vist.ly/3z86m

PharmaScrip's tweet card. Yeytuo will have remaining challenges to PrEP to overcome, while Kisunla’s label reflects dosing titration data from a Phase IIIb study to mitigate ARIA-E.

163

Scrip, Citeline Commercial@PharmaScrip · Jul 25

Bristol Appoints AstraZeneca’s Massacesi As Next CMO — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3z8bw vist.ly/3z8bx

PharmaScrip's tweet card. Chief Medical Officer Samit Hirawat will step down to pursue new career opportunities, the company said.

152

Scrip, Citeline Commercial@PharmaScrip · Jul 25

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3z7ks vist.ly/3z7kt

PharmaScrip's tweet card. Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

121

Scrip, Citeline Commercial@PharmaScrip · Jul 25

GSK’s Blenrep US Setback Could Go From Bad To Worse — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3z7cj vist.ly/3z7ck

PharmaScrip's tweet card. With a US approval any time soon now looking unlikely, analysts are revising Blenrep’s peak sales guidance downwards.

137

Scrip, Citeline Commercial@PharmaScrip · Jul 25

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025 — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3z6y9 vist.ly/3z6ya

PharmaScrip's tweet card. The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

132

Scrip, Citeline Commercial@PharmaScrip · Jul 25

More Pressure on Elevidys As The EU’s CHMP Says ‘No’ — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3z6jz vist.ly/3z6j2

PharmaScrip's tweet card. Just days after Roche stopped shipments of the DMD gene therapy following safety concerns raised by two patient deaths, its EU approval application has hit a block.

118

Scrip, Citeline Commercial@PharmaScrip · Jul 25

Executives On The Move: Three New CEOs Among This Week’s Changes — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3z5m7 vist.ly/3z5m8

PharmaScrip's tweet card. Recent moves in the industry include changes at the top at Trogenix and Quetzal Therapeutics, plus Synendos Therapeutics gains a new CMO from Roche.

107

Scrip, Citeline Commercial@PharmaScrip · Jul 25

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3z59z vist.ly/3z592

PharmaScrip's tweet card. Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in...

150

Scrip, Citeline Commercial@PharmaScrip · Jul 24

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3z4d8 vist.ly/3z4d9

PharmaScrip's tweet card. In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

146

Scrip, Citeline Commercial@PharmaScrip · Jul 24

AZ Poised To Bring Self-Administered C5 Inhibitor To Market — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3z48p vist.ly/3z48q

PharmaScrip's tweet card. Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

129

Scrip, Citeline Commercial@PharmaScrip · Jul 24

Rocket Comes Back To Earth With Restructuring Plan — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3z456 vist.ly/3z457

PharmaScrip's tweet card. The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.

119

Scrip, Citeline Commercial@PharmaScrip · Jul 24

Roche Keen To Cut Out The Middle Men On US Pricing — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3z336 vist.ly/3z337

PharmaScrip's tweet card. The Swiss giant has been talking to the US government about selling medicines directly to patients.

142

Scrip, Citeline Commercial@PharmaScrip · Jul 24

Leo Looks To Grow In US After Hand Eczema Cream Approval — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3yzqk vist.ly/3yzqm

PharmaScrip's tweet card. The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

108

Scrip, Citeline Commercial@PharmaScrip · Jul 24

Obesity Beyond GLP-1s: Amylins – The Next Frontier — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3yzge vist.ly/3yzgf

PharmaScrip's tweet card. In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists,...

150

Scrip, Citeline Commercial@PharmaScrip · Jul 24

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3yysq vist.ly/3yysr

PharmaScrip's tweet card. Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through,...

162

Scrip, Citeline Commercial@PharmaScrip · Jul 23

Roche, Following Sarepta, Pauses Elevidys Shipments In Certain Countries — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3yxw2 vist.ly/3yxx3

PharmaScrip's tweet card. Roche paused shipments of the Duchenne muscular dystrophy gene therapy in countries that reference US FDA approval of Elevidys after the agency asked Sarepta to pause US shipments; it remains...

240

Scrip, Citeline Commercial@PharmaScrip · Jul 23

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3yxs5 vist.ly/3yxs6

PharmaScrip's tweet card. With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

159

Scrip, Citeline Commercial@PharmaScrip · Jul 23

Where Next For Biologics In COPD After Roche’s Astegolimab Phase III Missfire? — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3yx45 vist.ly/3yx46

PharmaScrip's tweet card. The Phase III failure could dent Roche’s hopes of entering the COPD market with its novel therapy, despite its success in a large Phase IIb trial. It also marks another disappointment for the...

145

Scrip, Citeline Commercial@PharmaScrip · Jul 23

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’ — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3ywjr vist.ly/3ywjs

119

Scrip, Citeline Commercial@PharmaScrip · Jul 23

Abivax Over The Moon As Obefazimod Storms Phase III — Click image below to read more! || #Scrip | Start your free trial today: vist.ly/3yw4t vist.ly/3yw4u

PharmaScrip's tweet card. Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

270